Evaluation of the Effect of Alkaloid Berberine on the Positive and Negative Symptoms of the Patients with Schizophrenia: A Double-Blind Randomized Placebo-Controlled Clinical Trial
-
Ebrahim Moghimi Sarani
,
Fatemeh Ghorbannezhad
,
Mohammad Hassan Meshkibaf
,
Marjan Shakibaee
,
Seyed Hamdollah Mosavat
Abstract
Schizophrenia is a severe psychiatric condition that affects approximately 1% of the global population. Over the last decade, the efficacy of berberine as a complementary therapy in psychiatric diseases without significant side effects has been demonstrated. Therefore, this study assessed the effect of alkaloid berberine on the positive and negative symptoms in patients with schizophrenia. From December 2020 to March 2021, a total of 86 patients with schizophrenia who were referred to Shiraz Ebne Sina Hospital in South of Iran were divided into two groups; 42 patients with schizophrenia in the placebo group received risperidone at a dosage of 4-6 mg per day, and 44 patients in the treatment group, in addition to risperidone, received berberine at a dosage of 500 mg per day. This treatment regimen was followed for 30 days. The Positive and Negative Syndrome Scale (PANSS) was used to assess the patients’ symptoms. According to data analysis, The PANSS score in both groups showed a statistically significant decrease after 30 days (p < 0.05); however, this decreasing trend was not statistically significant between the groups (p > 0.05). The current study showed that complementary use of alkaloid berberine capsule with a dose of 500 mg per day did not show better outcomes compared with the placebo in patients with schizophrenia.
Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med 2005;2:e141.
Patel KR, Cherian J, Gohil K, Atkinson D. Schizophrenia: overview and treatment options. Pharmacy and Therapeutics. 2014;39(9):638-645.
Häfner H. From onset and prodromal stage to a life-long course of schizophrenia and its symptom dimensions: how sex, age, and other risk factors influence incidence and course of illness. Psychiatry J 2019:9804836..
Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, et al. Pharmacotherapy: A Pathophysiologic Approach. McGraw-Hill Medical. New York 2014.
Hill SK, Reilly JL, Keefe RS, Gold JM, Bishop JR, et al. Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. Am J Psychiatry 2013;170:1275-1284.
Correll CU, Schooler NR. Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat 2020;16:519-534.
Seidman LJ, Mirsky AF. Evolving notions of schizophrenia as a developmental neurocognitive disorder. J Int Neuropsychol Soc 2017;23:881-892.
Galderisi S, Mucci A, Buchanan RW, Arango C. Negative symptoms of schizophrenia: new developments and unanswered research questions. Lancet Psychiatry 2018;5:664-677.
Tollefson GD, Beasley Jr CM, Tran PV, Street JS, Krueger JA, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-465.
Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-564.
Bj S, Va S. Comprehensive textbook of psychiatry. Lippincott Williams and Wilkins. Philadelphia 2005.
Bobes J, Cañas F, Rejas J, Mackell J. Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:1287-1297.
Tarrago T, Kichik N, Seguí J, Giralt E. The natural product berberine is a human prolyl oligopeptidase inhibitor. ChemMedChem 2007;2:354-359.
Stroup TS, Alves WM, Hamer RM, Lieberman JA. Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. Nat Rev Drug Discov 2006;5:133-146.
Sarris J, Kavanagh DJ, Byrne G. Adjuvant use of nutritional and herbal medicines with antidepressants, mood stabilizers and benzodiazepines. J Psychiatr Res 2010;44:32-41.
Rathbone J, Zhang L, Zhang M, Xia J, Liu X, et al. Chinese herbal medicine for schizophrenia: cochrane systematic reiew of randomised trials. Br J Psychiatry 2007;190:379-384.
Kumari R, Kaundal M, Ahmad Z, Ashwalayan V. Herbal and dietary supplements in treatment of schizophrenia: An approach to improve therapeutics. Int J Pharm Sci Rev Res 2011;10:217-224.
Anna M. Evaluation of Anticonvulsant Activity of Chloroform Root Extract of Aconitum Heterophyllum. KMCH College of Pharmacy. Coimbatore 2017.
Piyabhan P, Wetchateng T. Bacopa monnieri (Brahmi) enhanced cognitive function and prevented cognitive impairment by increasing VGLUT2 immunodensity in prefrontal cortex of sub-chronic phencyclidine rat model of schizophrenia. J Med Assoc Thai 2015;98:S7-S15.
Lodha S, Upadhyay S. Review on the role of herbs in schizophrenia. Pharmacogn Commun 2021;11:78-80.
Och A, Podgórski R, Nowak R. Biological activity of berberine-a summary update. Toxins 2020;12:713.
Kumar A, Chopra K, Mukherjee M, Pottabathini R, Dhull DK. Current knowledge and pharmacological profile of berberine: an update. Eur J Pharmacol 2015;761:288-297.
Wang X, Wang R, Xing D, Su H, Ma C, et al. Kinetic difference of berberine between hippocampus and plasma in rat after intravenous administration of Coptidis rhizoma extract. Life Sci 2005;77:3058-3067.
Kulkarni S, Dhir A. Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders. Phytother Res 2010;24:317-324.
Chu H, Jin G, Friedman E, Zhen X. Recent development in studies of tetrahydroprotoberberines: mechanism in antinociception and drug addiction. Cell Mol Neurobiol 2008;28:491-499.
Kim Y-K, Choi J, Park S-C. A novel bio-psychosocial-behavioral treatment model in schizophrenia. Int J Mol Sci 2017;18:734.
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophre Bull 1987;13:261-276.
Omranifard V, Karahmadi M, Jannesari Z, Maracy M. Efficacy of modified compliance therapy for schizophrenia patients. J Res Med Sci 2012;17:S258-S263.
Bigdeli I, Farzin A, Talepasand S. Prospective memory impairments in schizophrenic patients. Iran J Psychiatry Behav Sci 2014;8:57-63.
Boyda HN, Procyshyn RM, Tse L, Yuen JW, Honer WG, et al. A comparison of the metabolic side-effects of the second-generation antipsychotic drugs risperidone and paliperidone in animal models. PloS One 2021;16:e0246211.
Li Z, Geng Y-N, Jiang J-D, Kong W-J. Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus. Evid-Based Complement Altern Med 2014;2014: 289264.
El khalki L, Tilaoui M, Jaafari A, Ait Mouse H, Zyad A. Studies on the dual cytotoxicity and antioxidant properties of Berberis vulgaris extracts and its main constituent berberine. Adv Pharmacol Sci 2018;2018:3018498.
Li M, Liu Y, Qiu Y, Zhang J, Zhang Y, et al. The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial. Psychiatry Res 2021;300:113899.
Fan J, Zhang K, Jin Y, Li B, Gao S, et al. Pharmacological effects of berberine on mood disorders. J Cell Mol Med 2019;23:21-28.
Ananth J, Parameswaran S, Gunatilake S. Side effects of atypical antipsychotic drugs. Curr Pharm Des 2004;10:2219-2229.
Kysenius K, Brunello CA, Huttunen HJ. Mitochondria and NMDA receptor-dependent toxicity of berberine sensitizes neurons to glutamate and rotenone injury. PloS One 2014;9:e107129.
Gunes M, Altindag A, Bulut M, Demir S, Ibiloglu AO, et al. Oxidative metabolism may be associated with negative symptoms in schizophrenia. Psychiatr Clin Psychopharmacol 2017;27:54-61.
Kawano M, Takagi R, Kaneko A, Matsushita S. Berberine is a dopamine D1-and D2-like receptor antagonist and ameliorates experimentally induced colitis by suppressing innate and adaptive immune responses. J Neuroimmunol 2015;289:43-55.
Wang Y, Tong Q, Ma S-R, Zhao Z-X, Pan L-B, et al. Oral berberine improves brain dopa/dopamine levels to ameliorate Parkinson’s disease by regulating gut microbiota. Signal Transduct Target Ther 2021;6:1-20.
| Files | ||
| Issue | Vol 7, No 3, 2022 | |
| Section | Research Article(s) | |
| DOI | https://doi.org/10.18502/tim.v7i3.10769 | |
| Keywords | ||
| Alkaloid berberine Positive and negative syndrome scale (PANSS) Schizophrenia | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
